RecruitingNot Applicable

Al18F-NOTA-LM3 PET/CT in Patients With TIO

China40 participantsStarted 2023-03-30

Plain-language summary

This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18 to 80 years. * Suspected or confirmed TIO patients. Exclusion Criteria: * Combined with other types of tumors. * Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min). * Pregnant or breast-feeding women. * Inability to perform PET/CT scans.

What they're measuring

Diagnostic value

Timeframe: From study completion to 6 months after completion.

Trial details

NCT IDNCT07366099

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-28

Contact for this trial

Hongli Jing

18600586399 annsmile1976@sina.com

View on ClinicalTrials.gov More Tumor-Induced Osteomalacia trials